文献速递淋巴瘤

利妥昔单抗时代滤泡性淋巴瘤组织学转化的风险及转化后生存:西班牙GELTAMO组回顾性多中心研究

Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group.
PubMed 文献 · Br J Haematol · 2017-08-07

西班牙GELTAMO组回顾性多中心研究纳入1734例1-3A级滤泡性淋巴瘤患者,中位随访6.2年,106例发生组织学转化,10年累积转化发生率为8%。高危FLIPI和非一线治疗无效与转化风险相关;转化后一线治疗有效、自体干细胞移植和修订版IPI与转化后生存显著相关。

要点

  • 10年组织学转化累积发生率为8%,106例转化患者中位转化时间2.5年。
  • 高危FLIPI(HR 2.6)和非一线治疗无效(HR 2.9)与组织学转化风险相关。
  • 转化后一线治疗有效(HR 5.3)、自体干细胞移植(HR 3.9)和修订版IPI(HR 2.2)与转化后生存显著相关。

核心结论

  • 在利妥昔单抗时代,治疗反应和组织学转化是与生存最显著相关的变量。
  • 需要更好的治疗以提高治疗反应,并且必须将组织学转化纳入新药临床试验。

研究设计与样本

  • 西班牙Grupo Español de Linfoma y Transplante Autólogo de Médula Ósea开展的回顾性观察性多中心研究,纳入1734例(800例男性/934例女性;中位年龄59岁)诊断为1-3A级滤泡性淋巴瘤的患者。

主要发现

  • 中位随访6.2年,106例发生组织学转化,10年累积转化发生率为8%。
  • 106例转化患者的中位转化时间为2.5年。
  • 高危滤泡性淋巴瘤国际预后指数(FLIPI)与组织学转化相关(HR 2.6,95%CI:1.5-4.5),一线治疗无效与组织学转化相关(HR 2.9,95%CI:1.3-6.8)。
  • 106例转化患者中70例死亡,5年转化后生存率为26%。
  • 转化后一线治疗有效(HR 5.3,95%CI:2.4-12.0)、自体干细胞移植(HR 3.9,95%CI:1.5-10.1)和修订版国际预后指数(HR 2.2,95%CI:1.1-4.2)与转化后生存显著相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The diagnostic criteria for follicular lymphoma (FL) transformation vary among the largest series, which commonly exclude histologically-documented transformation (HT) mandatorily. The aims of this retrospective observational multicentre study by the Spanish Grupo Español de Linfoma y Transplante Autólogo de Médula Ósea, which recruited 1734 patients (800 males/934 females; median age 59 years), diagnosed with FL grades 1-3A, were, (i) the cumulative incidence of HT (CI-HT); (ii) risk factors associated with HT; and (iii) the role of treatment and response on survival following transformation (SFT). With a median follow-up of 6·2 years, 106 patients developed HT. Ten-year CI-HT was 8%. Considering these 106 patients who developed HT, median time to transformation was 2·5 years. High-risk FL International Prognostic Index [Hazard ratio (HR) 2·6, 95% confidence interval (CI): 1·5-4·5] and non-response to first-line therapy (HR 2·9, 95% CI: 1·3-6·8) were associated with HT. Seventy out of the 106 patients died (5-year SFT, 26%). Response to HT first-line therapy (HR 5·3, 95% CI: 2·4-12·0), autologous stem cell transplantation (HR 3·9, 95% CI: 1·5-10·1), and revised International Prognostic Index (HR 2·2, 95% CI: 1·1-4·2) were significantly associated with SFT. Response to treatment and HT were the variables most significantly associated with survival in the rituximab era. Better therapies are needed to improve response. Inclusion of HT in clinical trials with new agents is mandatory.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Alonso-Álvarez S, Magnano L, Alcoceba M, et al. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group. Br J Haematol. 2017. PMID: 28782811. doi:10.1111/bjh.14831

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。